BR112021009234A2 - Composições imunogênicas para tratamento de hepatite b - Google Patents

Composições imunogênicas para tratamento de hepatite b Download PDF

Info

Publication number
BR112021009234A2
BR112021009234A2 BR112021009234-0A BR112021009234A BR112021009234A2 BR 112021009234 A2 BR112021009234 A2 BR 112021009234A2 BR 112021009234 A BR112021009234 A BR 112021009234A BR 112021009234 A2 BR112021009234 A2 BR 112021009234A2
Authority
BR
Brazil
Prior art keywords
hbsag
hepatitis
antigen
aluminum
immunogenic composition
Prior art date
Application number
BR112021009234-0A
Other languages
English (en)
Portuguese (pt)
Inventor
David Evander Anderson
Tanvir Ahmed
Original Assignee
Variation Biotechnologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Variation Biotechnologies Inc filed Critical Variation Biotechnologies Inc
Publication of BR112021009234A2 publication Critical patent/BR112021009234A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
BR112021009234-0A 2018-11-13 2019-11-13 Composições imunogênicas para tratamento de hepatite b BR112021009234A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862760439P 2018-11-13 2018-11-13
US62/760,439 2018-11-13
PCT/IB2019/001230 WO2020099927A1 (en) 2018-11-13 2019-11-13 Immunogenic compositions for treatment of hepatitis b

Publications (1)

Publication Number Publication Date
BR112021009234A2 true BR112021009234A2 (pt) 2021-09-08

Family

ID=70731781

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021009234-0A BR112021009234A2 (pt) 2018-11-13 2019-11-13 Composições imunogênicas para tratamento de hepatite b

Country Status (10)

Country Link
US (2) US12128100B2 (https=)
EP (1) EP3880244A4 (https=)
JP (2) JP2022513001A (https=)
KR (1) KR102943479B1 (https=)
CN (2) CN118987191A (https=)
BR (1) BR112021009234A2 (https=)
IL (2) IL314712A (https=)
MX (1) MX2021005588A (https=)
WO (1) WO2020099927A1 (https=)
ZA (1) ZA202103976B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020099927A1 (en) 2018-11-13 2020-05-22 Variation Biotechnologies Inc. Immunogenic compositions for treatment of hepatitis b
US20240123060A1 (en) * 2019-06-21 2024-04-18 Variation Biotechnologies Inc. Improved therapeutic composition comprising hepatitis b antigen having s, pre-s1 and pre-s2 protein, aluminium phosphate and interferon-alpha and use thereof for treatment of hepatitis b
AU2024313135A1 (en) 2023-06-23 2026-01-22 Brii Biosciences, Inc. Assessment and treatment of chronic hepatitis b

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5242812A (en) 1989-02-07 1993-09-07 Bio-Technology General Corp. Method for production and purification of hepatitis B vaccine
MA22842A1 (fr) 1992-03-27 1993-10-01 Smithkline Beecham Biolog Procede de preparation de compositions de vaccin.
GB9503863D0 (en) 1995-02-25 1995-04-19 Smithkline Beecham Biolog Vaccine compositions
GB9809507D0 (en) * 1998-05-01 1998-07-01 Smithkline Beecham Biolog Novel composition
CN1305527C (zh) 2003-11-21 2007-03-21 薛平 乙型肝炎治疗疫苗及其制备方法
KR100836745B1 (ko) 2007-01-31 2008-06-10 (주)두비엘 Ｈｂｖ 백신 및 그의 제조 방법
CN102949717A (zh) 2012-07-06 2013-03-06 中国疾病预防控制中心病毒病预防控制所 一种含poly I:C佐剂的新型乙肝疫苗制剂
CN104043120B (zh) 2013-03-13 2017-05-31 南京赛威信生物医药有限公司 乙型肝炎疫苗
WO2018166298A1 (en) 2017-03-13 2018-09-20 Fudan University Immunopotentiator, immunotherapeutic pharmaceutical composition and its preparation and use
WO2020099927A1 (en) * 2018-11-13 2020-05-22 Variation Biotechnologies Inc. Immunogenic compositions for treatment of hepatitis b
US20240123060A1 (en) 2019-06-21 2024-04-18 Variation Biotechnologies Inc. Improved therapeutic composition comprising hepatitis b antigen having s, pre-s1 and pre-s2 protein, aluminium phosphate and interferon-alpha and use thereof for treatment of hepatitis b

Also Published As

Publication number Publication date
US20250269013A1 (en) 2025-08-28
EP3880244A1 (en) 2021-09-22
KR102943479B1 (ko) 2026-03-27
ZA202103976B (en) 2023-09-27
CA3119581A1 (en) 2020-05-22
KR20210151047A (ko) 2021-12-13
US12128100B2 (en) 2024-10-29
IL283039B1 (en) 2024-09-01
JP2024174990A (ja) 2024-12-17
CN113423423A (zh) 2021-09-21
MX2021005588A (es) 2021-08-11
IL283039A (en) 2021-06-30
WO2020099927A1 (en) 2020-05-22
EP3880244A4 (en) 2022-08-17
US20230079703A1 (en) 2023-03-16
IL283039B2 (en) 2025-01-01
IL314712A (en) 2024-10-01
JP2022513001A (ja) 2022-02-07
CN113423423B (zh) 2024-08-13
CN118987191A (zh) 2024-11-22

Similar Documents

Publication Publication Date Title
RU2160120C2 (ru) Комбинированная вакцина на основе поверхностного антигена вируса гепатита в, способ ее получения и способ предупреждения инфекции гепатита в у человека
JP6499592B2 (ja) Ｂ型肝炎ワクチン
US20250269013A1 (en) Immunogenic compositions for treatment of hepatitis b
PT2097102E (pt) Vacina de combinação tendo quantidades reduzidas de antigénio de poliovírus
ES2965709T3 (es) Composición farmacéutica que incluye los antígenos de superficie y nucleocápside del virus de la hepatitis B
CN110944662A (zh) 用于治疗和/或预防hbv感染的组合物及其用途
JP2022516041A (ja) Ｂ型肝炎を治療するための薬物製剤、その製造方法及び用途
BR112021007668A2 (pt) composições imunogênicas
EP3986459A1 (en) Improved therapeutic composition comprising hepatitis b antigen having s, pre-s1 and pre-s2 protein, aluminium phosphate and interferon-alpha and use thereof for treatment of hepatitis b
CA3119581C (en) Immunogenic compositions for treatment of hepatitis b
ES2386369T3 (es) Vacunas que comprenden la proteína de núcleo HBC truncado mas adyuvantes basados en saponina
WO2023280303A1 (zh) Avc-29作为疫苗佐剂的用途以及含有该佐剂的疫苗组合物
CN107693788A (zh) 一种用于预防或治疗乙型肝炎的药物组合物及其用途
ES2985391T3 (es) Métodos y composiciones para el tratamiento de la infección por hepatitis B
HK40050381A (en) Immunogenic compositions for treatment of hepatitis b
HK40050381B (zh) 用於治疗乙型肝炎的免疫原性组合物
JP2022548328A (ja) 生分解性ナノ複合体ワクチン、ｂ型肝炎ウイルス複製およびｂ型肝炎ウイルス表面抗原分泌の抑制方法
BR112018069738B1 (pt) Composição farmacêutica, e, uso da mesma
EA040981B1 (ru) Фармацевтическая композиция, которая включает поверхностные и нуклеокапсидные антигены вируса гепатита b
HK40015475A (en) A composition for treating and/or preventing hepatitis b virus infection and the use thereof

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]